Promoter Targeting ShRNA Suppresses HIV-1 Infection In Vivo Through Transcriptional Gene Silencing

Overview

Journal Mol Ther Nucleic Acids

Publisher Cell Press

Date 2013 Dec 5

PMID 24301868

Citations 31

Authors

Kazuo Suzuki

Shinichiro Hattori

Katherine Marks

Chantelle Ahlenstiel

Yosuke Maeda

Takaomi Ishida

Michelle Millington

Maureen Boyd

Geoff Symonds

David A Cooper

Seiji Okada

Anthony D Kelleher

Affiliations

Soon will be listed here.

Abstract

Despite prolonged and intensive application, combined antiretroviral therapy cannot eradicate human immunodeficiency virus (HIV)-1 because it is harbored as a latent infection, surviving for long periods of time. Alternative approaches are required to overcome the limitations of current therapy. We have been developing a short interfering RNA (siRNA) gene silencing approach. Certain siRNAs targeting promoter regions of genes induce transcriptional gene silencing. We previously reported substantial transcriptional gene silencing of HIV-1 replication by an siRNA targeting the HIV-1 promoter in vitro. In this study, we show that this siRNA, expressed as a short hairpin RNA (shRNA) (shPromA-JRFL) delivered by lentiviral transduction of human peripheral blood mononuclear cells (PBMCs), which are then used to reconstitute NOJ mice, is able to inhibit HIV-1 replication in vivo, whereas a three-base mismatched variant (shPromA-M2) does not. In shPromA-JRFL-treated mice, HIV-1 RNA in serum is significantly reduced, and the ratio of CD4(+)/CD8(+) T cells is significantly elevated. Expression levels of the antisense RNA strand inversely correlates with HIV-1 RNA in serum. The silenced HIV-1 can be reactivated by T-cell activation in ex vivo cultures. HIV-1 suppression is not due to offtarget effects of shPromA-JRFL. These data provide "proof-of principle" that an shRNA targeting the HIV-1 promoter is able to suppress HIV-1 replication in vivo.Molecular Therapy-Nucleic Acids (2013) 2, e137; doi:10.1038/mtna.2013.64; published online 3 December 2013.

Citing Articles

Harnessing antiviral RNAi therapeutics for pandemic viruses: SARS-CoV-2 and HIV.

Bowden-Reid E, Moles E, Kelleher A, Ahlenstiel C Drug Deliv Transl Res. 2025; .

PMID: 39833468 DOI: 10.1007/s13346-025-01788-x.

Current State of Therapeutics for HTLV-1.

Wang T, Hirons A, Doerflinger M, Morris K, Ledger S, Purcell D Viruses. 2024; 16(10).

PMID: 39459949 PMC: 11512412. DOI: 10.3390/v16101616.

A CRISPR/RfxCas13d-mediated strategy for efficient RNA knockdown in mouse embryonic development.

Zhang L, Cao S, Wu H, Yan M, Li J, Chen L Sci China Life Sci. 2024; 67(11):2297-2306.

PMID: 39110403 DOI: 10.1007/s11427-023-2572-6.

Advances in HIV Gene Therapy.

Kitawi R, Ledger S, Kelleher A, Ahlenstiel C Int J Mol Sci. 2024; 25(5).

PMID: 38474018 PMC: 10931721. DOI: 10.3390/ijms25052771.

MicroRNAs and long non-coding RNAs during transcriptional regulation and latency of HIV and HTLV.

Alpuche-Lazcano S, Scarborough R, Gatignol A Retrovirology. 2024; 21(1):5.

PMID: 38424561 PMC: 10905857. DOI: 10.1186/s12977-024-00637-y.

References

Wong J, Hezareh M, Gunthard H, Havlir D, Ignacio C, Spina C . Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science. 1997; 278(5341):1291-5. DOI: 10.1126/science.278.5341.1291. View

Colin L, Van Lint C . Molecular control of HIV-1 postintegration latency: implications for the development of new therapeutic strategies. Retrovirology. 2009; 6:111. PMC: 2797771. DOI: 10.1186/1742-4690-6-111. View

Della Chiara G, Crotti A, Liboi E, Giacca M, Poli G, Lusic M . Negative regulation of HIV-1 transcription by a heterodimeric NF-κB1/p50 and C-terminally truncated STAT5 complex. J Mol Biol. 2011; 410(5):933-43. DOI: 10.1016/j.jmb.2011.03.044. View

Das A, Brummelkamp T, Westerhout E, Vink M, Madiredjo M, Bernards R . Human immunodeficiency virus type 1 escapes from RNA interference-mediated inhibition. J Virol. 2004; 78(5):2601-5. PMC: 369246. DOI: 10.1128/jvi.78.5.2601-2605.2004. View

Turner A, de la Cruz J, Morris K . Mobilization-competent Lentiviral Vector-mediated Sustained Transcriptional Modulation of HIV-1 Expression. Mol Ther. 2008; 17(2):360-8. PMC: 2835059. DOI: 10.1038/mt.2008.268. View

Hornung V, Guenthner-Biller M, Bourquin C, Ablasser A, Schlee M, Uematsu S . Sequence-specific potent induction of IFN-alpha by short interfering RNA in plasmacytoid dendritic cells through TLR7. Nat Med. 2005; 11(3):263-70. DOI: 10.1038/nm1191. View

Mette M, Matzke A, Matzke M . Resistance of RNA-mediated TGS to HC-Pro, a viral suppressor of PTGS, suggests alternative pathways for dsRNA processing. Curr Biol. 2001; 11(14):1119-23. DOI: 10.1016/s0960-9822(01)00315-3. View

Boden D, Pusch O, Lee F, Tucker L, Ramratnam B . Human immunodeficiency virus type 1 escape from RNA interference. J Virol. 2003; 77(21):11531-5. PMC: 229317. DOI: 10.1128/jvi.77.21.11531-11535.2003. View

Roberts T, El Andaloussi S, Morris K, McClorey G, Wood M . Small RNA-Mediated Epigenetic Myostatin Silencing. Mol Ther Nucleic Acids. 2013; 1:e23. PMC: 3390243. DOI: 10.1038/mtna.2012.15. View

10.

Westerhout E, Ooms M, Vink M, Das A, Berkhout B . HIV-1 can escape from RNA interference by evolving an alternative structure in its RNA genome. Nucleic Acids Res. 2005; 33(2):796-804. PMC: 548362. DOI: 10.1093/nar/gki220. View

11.

Suzuki K, Ishida T, Yamagishi M, Ahlenstiel C, Swaminathan S, Marks K . Transcriptional gene silencing of HIV-1 through promoter targeted RNA is highly specific. RNA Biol. 2011; 8(6):1035-46. PMC: 3256422. DOI: 10.4161/rna.8.6.16264. View

12.

Jacque J, Triques K, Stevenson M . Modulation of HIV-1 replication by RNA interference. Nature. 2002; 418(6896):435-8. PMC: 9524216. DOI: 10.1038/nature00896. View

13.

Weinberg M, Villeneuve L, Ehsani A, Amarzguioui M, Aagaard L, Chen Z . The antisense strand of small interfering RNAs directs histone methylation and transcriptional gene silencing in human cells. RNA. 2005; 12(2):256-62. PMC: 1370905. DOI: 10.1261/rna.2235106. View

14.

Turunen M, Lehtola T, Heinonen S, Assefa G, Korpisalo P, Girnary R . Efficient regulation of VEGF expression by promoter-targeted lentiviral shRNAs based on epigenetic mechanism: a novel example of epigenetherapy. Circ Res. 2009; 105(6):604-9. DOI: 10.1161/CIRCRESAHA.109.200774. View

15.

Judge A, Sood V, Shaw J, Fang D, McClintock K, MacLachlan I . Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA. Nat Biotechnol. 2005; 23(4):457-62. DOI: 10.1038/nbt1081. View

16.

Malecova B, Morris K . Transcriptional gene silencing through epigenetic changes mediated by non-coding RNAs. Curr Opin Mol Ther. 2010; 12(2):214-22. PMC: 2861437. View

17.

Ho D, Neumann A, Perelson A, Chen W, Leonard J, Markowitz M . Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature. 1995; 373(6510):123-6. DOI: 10.1038/373123a0. View

18.

Neff C, Zhou J, Remling L, Kuruvilla J, Zhang J, Li H . An aptamer-siRNA chimera suppresses HIV-1 viral loads and protects from helper CD4(+) T cell decline in humanized mice. Sci Transl Med. 2011; 3(66):66ra6. PMC: 3138523. DOI: 10.1126/scitranslmed.3001581. View

19.

Shah P, Pham N, Schaffer D . HIV develops indirect cross-resistance to combinatorial RNAi targeting two distinct and spatially distant sites. Mol Ther. 2012; 20(4):840-8. PMC: 3321590. DOI: 10.1038/mt.2012.3. View

20.

Jones L, Ratcliff F, Baulcombe D . RNA-directed transcriptional gene silencing in plants can be inherited independently of the RNA trigger and requires Met1 for maintenance. Curr Biol. 2001; 11(10):747-57. DOI: 10.1016/s0960-9822(01)00226-3. View